GLP-1 receptor agonists have become central to modern weight management and diabetes care, yet practitioners often find themselves answering questions about side effects without consistent, evidence-based guidance. MJ Clinical Training, founded by pharmacists Mo Ahmad and Jella Kang, recognises that informed practitioners deliver better patient outcomes. This guide provides the clinical perspective you need to confidently discuss GLP-1 side effects with patients, setting realistic expectations and supporting adherence to treatment.
Patient adherence to GLP-1 therapy significantly improves when individuals understand potential side effects before starting treatment. Research shows that patients who receive thorough, honest information about adverse effects are more likely to persist with therapy, even when experiencing mild symptoms. Conversely, unexpected side effects are a leading cause of treatment discontinuation.
As a practitioner, your role extends beyond prescribing—you’re educating patients about what to expect and when symptoms warrant further investigation. This proactive approach builds trust and ensures patients can distinguish between expected, self-limiting effects and those requiring intervention. CPD-accredited training emphasises this communication skill as integral to clinical practice.
Gastrointestinal effects—nausea, vomiting, diarrhoea, and constipation—are the most commonly reported adverse effects of GLP-1 therapy. The incidence and severity depend on the specific medication, dosing schedule, and individual patient factors. Nausea occurs in 20-40% of patients, whilst gastrointestinal disturbances affect 15-30%.
Crucially, most GI effects are transient. Patients starting titrated dosing schedules typically experience symptoms that peak within the first 2-4 weeks, then gradually resolve as the body adapts. This is the conversation you need to have: frame GI side effects as temporary, expected, and manageable. Practical guidance includes dietary modification—smaller, less fatty meals; ensuring adequate hydration; and gradually increasing fibre intake. For moderate symptoms, antiemetics or antidiarrhoeal agents may provide bridge support. Importantly, vomiting that persists beyond 4 weeks or is severe warrants investigation for other causes. Dehydration risk increases if GI symptoms are pronounced, particularly in elderly patients or those with renal impairment.
Pancreatitis is a serious potential adverse effect of GLP-1 therapy, and patients often raise this concern. The evidence indicates that whilst acute pancreatitis has been reported, the actual incidence attributable to GLP-1 is debated and remains rare. Pharmacovigilance data suggests rates are comparable to or lower than in untreated type 2 diabetes populations.
Your guidance should emphasise red flag symptoms: severe abdominal pain, particularly if accompanied by elevated amylase or lipase, nausea, and vomiting unresponsive to standard treatment. Patients with personal or family history of pancreatitis require careful risk-benefit assessment and should not be reassured without considering their individual risk profile. This is precisely the nuanced clinical decision-making that CPD-accredited training equips you to deliver. GLP-1 should be discontinued if pancreatitis is suspected, pending investigation.
GLP-1 receptor agonists offer cardiovascular benefits for many patients, reducing major adverse cardiovascular events in trials. However, some patients report palpitations, dizziness, or symptoms suggesting hypotension. These effects warrant investigation, particularly in patients on concurrent antihypertensive medication.
Weight loss itself affects blood pressure and heart rate, so distinguishing GLP-1-specific effects from weight loss-related changes requires careful assessment. Blood pressure monitoring should be part of routine follow-up. Patients with significant weight loss may require medication adjustment as their cardiovascular physiology changes. This integrated approach—considering the broader clinical context rather than attributing all symptoms to GLP-1—is hallmark of experienced practitioners.
Thyroid concerns, thyroid neoplasms in animal studies, and retinopathy exacerbation in diabetic patients represent rare but clinically important considerations. Whilst human evidence for thyroid malignancy is lacking, patients with personal or family history of medullary thyroid carcinoma should be excluded from GLP-1 therapy. Diabetic retinopathy can worsen with rapid glucose normalisation and associated blood pressure changes; this is not GLP-1-specific but worth discussing with patients experiencing vision changes.
Gallstone formation has been reported with rapid weight loss across modalities. Practitioners should educate patients about abdominal symptoms and ensure appropriate investigation if acute symptoms develop. These discussions demonstrate your commitment to comprehensive care and patient safety.
How long do GLP-1 side effects typically last?
Most gastrointestinal side effects peak within 2-4 weeks and gradually resolve as the body adapts. Patients on titrated dosing schedules experience this more gradually than those on fixed-dose regimens. By 8-12 weeks, most patients report significant improvement. However, individual variation is substantial—some experience minimal effects, whilst others require longer adjustment periods.
Should I advise patients to stop GLP-1 if side effects occur?
Not necessarily. Early discontinuation means missing the period when adaptation typically occurs. Instead, discuss specific symptom management strategies: dietary modification, hydration, antiemetics if appropriate, and timeline expectations. Discontinuation should be considered if side effects are severe, persist beyond reasonable timeframes, or affect safety or quality of life significantly.
What investigations are needed before starting GLP-1?
Baseline assessment should include personal and family history of medullary thyroid carcinoma (contraindication), pancreatitis history, current medications (particularly other weight-loss agents), renal function, and blood glucose control. Thyroid function and lipid profile provide useful baselines. Cardiovascular assessment is prudent, particularly if on antihypertensive medications.
Are there patient populations where GLP-1 side effects are more concerning?
Yes. Elderly patients, those with renal impairment, and patients taking concurrent medications affecting gastric motility or blood pressure require closer monitoring. Pregnant women should not use GLP-1 therapy. Patients with gallstone history are at increased risk of gallstone-related complications with rapid weight loss. Individualised risk assessment is essential.
How should I document side effect discussions in patient records?
Document that you’ve discussed anticipated side effects, management strategies, when to seek medical attention, and expected timeline for symptom resolution. Document any specific concerns the patient raised and your responses. This creates an evidence trail of informed discussion and helps future practitioners understand the patient’s baseline expectations and concerns.
Phone: 07769 003219
Website: www.mjclinicaltraining.co.uk
Patient Retention Summer Patient Disengagement in Weight Management Clinics: Keeping GLP-1 Patients on Track Through the Holidays Holidays, disrupted routines, and quieter clinics mean summer
Clinical Skills Weight Loss Plateaus in Summer: How Clinicians Can Support Patients Through Stalls and Motivation Dips Summer holidays, disrupted routines, and the natural physiology
Clinical Practice Managing GLP-1 Supply Disruption in Weight Management Clinics: A Summer Continuity Guide for Clinicians Intermittent supply of GLP-1 receptor agonists is now
